近日,辽宁省药品及医用耗材集中采购网发布《关于执行来曲唑片等54个药品主动降价结果的通知》,其中由信达生物和劲方医药共同研发商业化的氟泽雷塞片备受瞩目,作为国内首个获批上市的KRAS G12C抑制剂,其价格从24900元降至18600元,降幅超25%。无独有偶,5月6日,江苏省公共资源交易中心发布《关于调整部分药品挂网价格的通知》,共涉及938个药品。其中,安斯泰来的FLT3抑制剂富马酸吉瑞替尼片...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.